CERo Therapeutics Holdings Management

Management criteria checks 0/4

CERo Therapeutics Holdings' CEO is Chris Ehrlich, appointed in Sep 2024, has a tenure of less than a year. directly owns 3.86% of the company’s shares, worth $851.92K. The average tenure of the management team and the board of directors is 0.1 years and 0.8 years respectively.

Key information

Chris Ehrlich

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	3.9%
Management average tenure	less than a year
Board average tenure	less than a year

Recent management updates

Recent updates

CEO

Chris Ehrlich (54 yo)

less than a year

Tenure

Mr. Christopher B. Ehrlich, M.B.A. also known as Chris, serves as Chief Executive Officer & Chair of CERo Therapeutics, Inc. Mr. Ehrlich was Director at ProLynx Inc since September 2022 until 2023. He serv...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Christopher Ehrlich	CEO & Chair	less than a year	no data	3.86% $ 851.9k
Brian Atwood	President & Director	no data	no data	13.13% $ 2.9m
Lawrence Corey	Co-founder & Head of Scientific Advisory Board	no data	no data	5.62% $ 1.2m
Andrew Kucharchuk	CFO & Director	less than a year	no data	0% $ 0
Kristen Pierce	Chief Development Officer & Director	less than a year	no data	0% $ 0

0.08yrs

Average Tenure

54yo

Average Age

Experienced Management: CERO's management team is not considered experienced ( 0.1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Christopher Ehrlich	CEO & Chair	less than a year	no data	3.86% $ 851.9k
Brian Atwood	President & Director	less than a year	no data	13.13% $ 2.9m
Lawrence Corey	Co-founder & Head of Scientific Advisory Board	no data	no data	5.62% $ 1.2m
Andrew Kucharchuk	CFO & Director	less than a year	no data	0% $ 0
Kristen Pierce	Chief Development Officer & Director	less than a year	no data	0% $ 0
Kathleen LaPorte	Independent Director	less than a year	no data	0.65% $ 142.9k
Shami Patel	Independent Director	less than a year	no data	no data
Adrian Bot	Scientific Advisor	no data	no data	no data
Antonio Lanzavecchia	Scientific Advisor	no data	no data	no data
Rafi Ahmed	Scientific Advisor	no data	no data	no data
Michael Byrnes	Independent Director	less than a year	no data	0% $ 0
Lindsey Rolfe	Independent Director	less than a year	no data	0% $ 0

0.8yrs

Average Tenure

55yo

Average Age

Experienced Board: CERO's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

CERo Therapeutics Holdings Management

Management criteria checks 0/4

Key information

Recent management updates

CERo Therapeutics Holdings, Inc. Appoints Shami Patel to the Board as Class III Director

CERo Therapeutics Holdings, Inc. Appoints Andrew Albert Kucharchuk as Chief Financial Officer

High number of new and inexperienced directors

Recent updates

CERo Announces Reverse Stock Split to Regain Compliance with the Bid Price Requirement

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics Holdings, Inc. announced delayed 10-Q filing

Nasdaq Determines to Delist CERo Therapeutics Holdings' Securities from The Nasdaq Global Market on November 8, 2024 Due to Failure to Regain Compliance with the MVLS Requirement within the Cure Period

CERo Therapeutics Holdings Receives Low Price Deficiency Letter from Nasdaq and Nasdaq Determines to Delist its Securities from The Nasdaq Global Market

CERo Therapeutics Holdings, Inc. Announces Submission of IND Clinical Hold Complete Response Letter

CERo Therapeutics Holdings, Inc. Appoints Shami Patel to the Board as Class III Director

CERo Therapeutics Holdings, Inc. Appoints Andrew Albert Kucharchuk as Chief Financial Officer

CERo Therapeutics Holdings, Inc. announced that it expects to receive $1.2 million in funding

CERo Therapeutics Holdings, Inc. announced that it expects to receive $1.25 million in funding

CERo Therapeutics Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement and MVPHS Requirement

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

CERo Therapeutics Holdings, Inc. announced delayed 10-Q filing

CERo Therapeutics Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum $50 Million Market Value of Listed Securities Requirement Set Forth in Nasdaq Listing Rule 5450(b)(2)(A)

CERo Therapeutics Holdings, Inc. announced delayed annual 10-K filing

CERo Therapeutics Holdings, Inc. announced delayed annual 10-K filing

New major risk - Shareholder dilution

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients

Phoenix Biotech Acquisition Corp.(NasdaqGM:CERO) dropped from NASDAQ Composite Index

CERo Therapeutics Holdings, Inc. announced that it has received $9.4 million in funding

New minor risk - Share price stability

Phoenix Biotech Acquisition Corp. announced that it expects to receive $2 million in funding from Keystone Capital Partners LLC

High number of new and inexperienced directors

Phoenix Biotech Acquisition Corp. Receives Non-Compliance Letter from Nasdaq related to Listing Rule 5450(a)(2

Phoenix Biotech Acquisition Corp. Receives Non-Compliance Letter from Nasdaq related to Listing Rule 5450(a)(2

CERo Therapeutics, Inc. entered into a definitive business combination agreement to acquire Phoenix Biotech Acquisition Corp. (NasdaqGM : PBAX) in a reverse merger transaction for an implied enterprise value of approximately $110 million.

Phoenix Biotech Acquisition Corp. (NasdaqGM:PBAX) entered into a business combination agreement to acquire Intrinsic Medicine, Inc. for approximately $140 million.

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age